Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1982 2
1984 2
1985 2
1986 2
1987 1
1991 1
1996 3
1997 2
1998 6
1999 3
2000 3
2001 10
2002 6
2003 6
2004 3
2005 5
2006 10
2007 6
2008 12
2009 5
2010 9
2011 7
2012 12
2013 15
2014 5
2015 7
2016 9
2017 13
2018 14
2019 10
2020 10
2021 19
2022 23
2023 14
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. Among authors: heneghan ma. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Among authors: heneghan ma. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Reply.
Rahim MN, Heneghan MA. Rahim MN, et al. Among authors: heneghan ma. Liver Transpl. 2019 Oct;25(10):1590-1591. doi: 10.1002/lt.25611. Epub 2019 Aug 20. Liver Transpl. 2019. PMID: 31344310 No abstract available.
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. Schattenberg JM, et al. Among authors: heneghan ma. J Hepatol. 2021 Jun;74(6):1344-1354. doi: 10.1016/j.jhep.2021.01.013. Epub 2021 Jan 21. J Hepatol. 2021. PMID: 33484775 Free article. Clinical Trial.
Autoimmune hepatitis.
Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Heneghan MA, et al. Lancet. 2013 Oct 26;382(9902):1433-44. doi: 10.1016/S0140-6736(12)62163-1. Epub 2013 Jun 14. Lancet. 2013. PMID: 23768844 Review.
Reply.
Chung Y, Heneghan MA. Chung Y, et al. Among authors: heneghan ma. Hepatology. 2022 Sep;76(3):E67-E68. doi: 10.1002/hep.32579. Epub 2022 Jun 11. Hepatology. 2022. PMID: 35587539 No abstract available.
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, Lenzi M, Trauner M, Manns MP, Vierling JM, Montano-Loza AJ, Lohse AW, Schramm C, Drenth JPH, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG) collaborators(‡). Pape S, et al. Among authors: heneghan ma. J Hepatol. 2022 Apr;76(4):841-849. doi: 10.1016/j.jhep.2021.12.041. Epub 2022 Jan 20. J Hepatol. 2022. PMID: 35066089 Free article.
Reply.
Rahim MN, Heneghan MA. Rahim MN, et al. Among authors: heneghan ma. Liver Transpl. 2019 Sep;25(9):1457-1458. doi: 10.1002/lt.25606. Liver Transpl. 2019. PMID: 31323692 No abstract available.
Pregnancy in Liver Transplantation.
Rahim MN, Long L, Penna L, Williamson C, Kametas NA, Nicolaides KH, Heneghan MA. Rahim MN, et al. Among authors: heneghan ma. Liver Transpl. 2020 Apr;26(4):564-581. doi: 10.1002/lt.25717. Liver Transpl. 2020. PMID: 31950556 Review.
Non-invasive strategies to predict post-hepatectomy liver failure.
Cavazza A, Heneghan MA. Cavazza A, et al. Among authors: heneghan ma. Hepatobiliary Surg Nutr. 2024 Jun 1;13(3):533-535. doi: 10.21037/hbsn-24-219. Epub 2024 May 24. Hepatobiliary Surg Nutr. 2024. PMID: 38911211 Free PMC article. No abstract available.
234 results